Verici Dx Plc (VRCI) ORD GBP0.001
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
Verici Dx reaches Thermo Fisher collaboration milestone
1 July 2024 13:34
(Sharecast News) - Verici Dx, a developer of advanced clinical diagnostics for organ transplants, announced a significant milestone achievement under its agreement with Thermo Fisher Scientific on Monday.
-
Verici Dx completes analytical validation on two assays
15 February 2022 14:28
(Sharecast News) - Clinical diagnostics developer Verici Dx announced on Tuesday that its two lead in-vitro diagnostic assays, 'Clarava' and 'Tuteva', had completed analytical validation...
-
Verici Dx enters collaboration with Nasdaq-listed Illumina
5 January 2022 12:54
(Sharecast News) - Organ transplant clinical diagnosis developer Verici Dx announced a collaboration with Nasdaq-listed Illumina on Wednesday, to expedite the operational launch of data analysis processing...
-
Verici granted 'fundamental' codes for tests in US market
4 January 2022 16:05
(Sharecast News) - Organ transplant diagnostics company Verici Dx has been granted 'CPT' proprietary laboratory analyses (PLA) codes for both its 'Clarava' and 'Tuteva' tests by...
-
Verici enrols patients for multi-centre study ahead of forecast
31 August 2021 12:32
(Sharecast News) - Organ transplant diagnostics developer Verici Dx announced on Tuesday that patient enrolment for a multi-centre observational clinical validation study for its lead products had concluded...
Company announcements Announcements
-
Half-year Report
15 July 2024 07:00
Verici DX
-
Notice of Results and Business Update
11 July 2024 14:00
Verici DX
-
Significant milestone re Thermo Fisher agreement
1 July 2024 07:00
Verici DX
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.